ArticleCardiovascular and interventional radiology2025
Impact on Sexual Function of Protective Coil Embolization of Penile Collaterals During Prostatic Artery Embolization.
Article in Cardiovascular and interventional radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Research progress on ejaculatory function preservation in minimally invasive surgical treatments for benign prostatic hyperplasia: a narrative review.Translational andrology and urology · 2025Review
- Benign Prostatic Hyperplasia and Sexual Dysfunction: Review of the Impact of New Medical and Surgical Therapies on Sexual Health.Current urology reports · 2025Review
- Penile Collaterals During PAE; Perilous Headache with Safe Remedy.Cardiovascular and interventional radiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aims to evaluate the erectile and ejaculatory function of patients undergoing prostate artery embolization with coil embolization of penile collaterals (cPAE) compared to traditional PAE (tPAE) for treating lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). MATERIALS AND
methods878 patients who underwent PAE for LUTS secondary to BPH at a single institution from September 2014 to September 2022 were assessed. 828 (94%) underwent tPAE, and 50 (6%) underwent cPAE. Sexual Health Inventory for Men (SHIM) and Ejaculatory Function Questionnaire (EJQ) scores were reviewed pre-procedure and at subsequent follow-ups.
resultsIn tPAE, the median (interquartile range (IQR), p-value compared to baseline) SHIM scores were 19(14-24, p = < 0.001), 19(13-18, p = 0.22), 19(16-23, p = 0.005), and 18(15-22, p = 0.52) at 3, 6, 12, and 24 months, respectively, from a baseline of 17(10-21). In cPAE, median-(IQR, p-value compared to baseline) SHIM scores were 16(6.5-22.5, p = 0.03), 13(6.8-16.3, p = 0.04), 8.5(5-1.5, p = 0.46), and 18(15-18, p = 1) at 3, 6, 12, and 24 months, respectively, from baseline of 13 (8-20). There was no significant difference in SHIM score change from baseline between cPAE and tPAE groups at 3(p = 0.60), 6(p = 0.31), 12(p = 0.09), and 24 months(p = 1) post-PAE. In tPAE, median(IQR, p-value compared to baseline)-EJQ scores were 16(13-18, p = 0.42), 16(13-18, p = 0.22), 17(12-19, p = 0.09), and 16(12.5-19, p = 1) at 3, 6, 12, and 24 months, respectively, from baseline of 14 (11-18). In cPAE group, median EJQ scores were 14(10.5-20, p = 0.11), 18(17-18), 16.5(3.5-19.7, p = 1) at 3, 6, and 12 months, respectively, from baseline of 15(12-18). There was no significant difference in EJQ score change from baseline between cPAE and tPAE groups at 3(p = 0.26), 6(p = 0.38), and 12(p = 0.88) months.
conclusionAdjunct coil embolization of penile collaterals during PAE for preventing nontarget embolization has no adverse effect on erectile or ejaculatory function.
Indexed as
Identifiers
39915324What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.